Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16572116 | 0.89 | L3MBTL1 (0.47) | L3MBTL1MAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL16572305 | 0.82 | MAPT (0.48) | L3MBTL1MAPTLMNASMN1; SMN2IDO1 | |
| SCHEMBL15804399 | 0.81 | PPARA (0.45) | MAPTSYKKLK7KLK5 | |
| SCHEMBL15804461 | 0.80 | KLK5 (0.44) | MAPTSYKKLK7KLK5 | |
| SCHEMBL15804395 | 0.80 | KLK7 (0.44) | MAPTSYKKLK7KLK5 | |
| SCHEMBL15802568 | 0.80 | KLK7 (0.45) | MAPTSYKKLK7KLK5 | |
| SCHEMBL17194119 | 0.80 | KLK7 (0.45) | MAPTSYKKLK7KLK5 | |
| SCHEMBL15804500 | 0.79 | KLK7 (0.47) | MAPTSYKKLK7KLK5 | |
| SCHEMBL15802569 | 0.78 | KLK7 (0.44) | MAPTSYKKLK7KLK5 | |
| SCHEMBL17194117 | 0.78 | KLK7 (0.44) | MAPTSYKKLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160122306-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | PARION SCIENCES, INC. (US) | 2016-05-05 | — | — | US | disclosed |
| US-9260398-B2 | Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases | PARION SCIENCES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150099764-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | PARION SCIENCES, INC. (US) | 2015-04-09 | — | — | US | disclosed |
| US-8980898-B2 | Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases | PARION SCIENCES, INC. (US) | 2015-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099764-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | SCNN1B, SCNN1A, SCNN1G | L3MBTL1 4875/4885MAPT 3343/4885LMNA 2326/4885 |
| US-20160122306-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | SCNN1B, SCNN1A, SCNN1G | L3MBTL1 4875/4885MAPT 3343/4885LMNA 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.